Mark Alan Goldberg

Insider Reports History

Location: Lexington, MA
Owner filing signature: /s/ Melissa Masse, Attorney-in-Fact
Transaction evidence: Report rows are grouped by the transaction date disclosed in the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Reported holdings for Mark Alan Goldberg

Form 4 holding Director

GLYCOMIMETICS INC

Security class: Common Stock
Shares / value: 24,828
Estimated value: $74,484
Report date: 29 Mar 2024
Price: $3.00
Ownership: Direct

Form 4 holding Director

GLYCOMIMETICS INC

Security class: Common Stock
Shares / value: 11,497
Estimated value: $34,491
Report date: 29 Mar 2024
Price: $3.00
Ownership: By family trusts

Form 4 holding Director

Blueprint Medicines Corp

Security class: Common Stock
Shares / value: 0
Estimated value: $0
Report date: 17 Jul 2025
Price: $128.18
Ownership: Direct

Form 4 holding Director

ImmunoGen, Inc.

Security class: Common Stock
Shares / value: 0
Estimated value: $0
Report date: 12 Feb 2024
Price: $29.30
Ownership: Direct

Form 4 holding Director

ImmunoGen, Inc.

Security class: Deferred Share Unit
Shares / value: 0
Estimated value: $0
Report date: 12 Feb 2024
Price: $29.30
Ownership: Direct
Underlying class: Common Stock
Underlying amount

Form 4 holding Director

ImmunoGen, Inc.

Security class: Restricted Stock Unit
Shares / value: 0
Estimated value: $0
Report date: 12 Feb 2024
Price: $29.30
Ownership: Direct
Underlying class: Common Stock
Underlying amount

Form 4 holding Director

GLYCOMIMETICS INC

Security class: Stock Option (right to buy)
Shares / value: 40,000
Estimated value
Report date: 01 May 2024
Price
Ownership: Direct
Underlying class: Common Stock
Underlying amount

Form 4 holding Director

IDERA PHARMACEUTICALS, INC.

Security class: Stock Option (Right to Buy)
Shares / value: 26,000
Estimated value
Report date: 23 Jun 2022
Price
Ownership: Direct
Underlying class: Common Stock
Underlying amount

Form 4 holding Director

Blueprint Medicines Corp

Security class: Stock Option (Right to Buy)
Shares / value: 0
Estimated value
Report date: 17 Jul 2025
Price
Ownership: Direct
Underlying class: Common Stock
Underlying amount

Form 4 holding Director

ImmunoGen, Inc.

Security class: Stock Option (Right to Buy)
Shares / value: 0
Estimated value
Report date: 12 Feb 2024
Price: $4.56
Ownership: Direct
Underlying class: Common Stock
Underlying amount

Insider Reports Filed by Mark Alan Goldberg

4 BPMC

Blueprint Medicines Corp

Report period: 17 Jul 2025
Transactions: 10
Transaction value: $0
Accepted by SEC: 21 Jul 2025, 19:46
Role: Director
Next action: Open filing details

4 BPMC

Blueprint Medicines Corp

Report period: 18 Jun 2025
Transactions: 1
Transaction value: +$499,924
Accepted by SEC: 24 Jun 2025, 16:26
Role: Director
Next action: Open filing details

4 BPMC

Blueprint Medicines Corp

Report period: 12 Jun 2024
Transactions: 2
Transaction value: $0
Accepted by SEC: 14 Jun 2024, 17:34
Role: Director
Next action: Open filing details

4 GLYC

GLYCOMIMETICS INC

Report period: 01 May 2024
Transactions: 1
Transaction value: $0
Accepted by SEC: 01 May 2024, 16:30
Role: Director
Next action: Open filing details

4 GLYC

GLYCOMIMETICS INC

Report period: 29 Mar 2024
Transactions: 1
Transaction value: +$13,752
Accepted by SEC: 02 Apr 2024, 16:05
Role: Director
Next action: Open filing details

4

ImmunoGen, Inc.

Report period: 12 Feb 2024
Transactions: 13
Transaction value: $0
Accepted by SEC: 12 Feb 2024, 16:42
Role: Director
Next action: Open filing details

4

ImmunoGen, Inc.

Report period: 29 Dec 2023
Transactions: 1
Transaction value: +$16,871
Accepted by SEC: 03 Jan 2024, 17:45
Role: Director
Next action: Open filing details

4 GLYC

GLYCOMIMETICS INC

Report period: 29 Dec 2023
Transactions: 1
Transaction value: +$13,752
Accepted by SEC: 02 Jan 2024, 16:05
Role: Director
Next action: Open filing details

4

ImmunoGen, Inc.

Report period: 30 Oct 2023
Transactions: 3
Transaction value: -$3,800
Accepted by SEC: 01 Nov 2023, 17:59
Role: Director
Next action: Open filing details

4 GLYC

GLYCOMIMETICS INC

Report period: 30 Sep 2023
Transactions: 1
Transaction value: +$13,750
Accepted by SEC: 03 Oct 2023, 16:15
Role: Director
Next action: Open filing details

4

ImmunoGen, Inc.

Report period: 29 Sep 2023
Transactions: 1
Transaction value: +$16,870
Accepted by SEC: 02 Oct 2023, 17:05
Role: Director
Next action: Open filing details

4

ImmunoGen, Inc.

Report period: 30 Jun 2023
Transactions: 1
Transaction value: +$16,870
Accepted by SEC: 05 Jul 2023, 17:53
Role: Director
Next action: Open filing details

4 BPMC

Blueprint Medicines Corp

Report period: 21 Jun 2023
Transactions: 2
Transaction value: $0
Accepted by SEC: 23 Jun 2023, 19:06
Role: Director
Next action: Open filing details

4

ImmunoGen, Inc.

Report period: 14 Jun 2023
Transactions: 2
Transaction value: $0
Accepted by SEC: 16 Jun 2023, 16:45
Role: Director
Next action: Open filing details

4 GLYC

GLYCOMIMETICS INC

Report period: 19 May 2023
Transactions: 1
Transaction value: $0
Accepted by SEC: 22 May 2023, 16:23
Role: Director
Next action: Open filing details

4

ImmunoGen, Inc.

Report period: 31 Mar 2023
Transactions: 1
Transaction value: +$16,873
Accepted by SEC: 04 Apr 2023, 16:51
Role: Director
Next action: Open filing details

4

ImmunoGen, Inc.

Report period: 30 Dec 2022
Transactions: 1
Transaction value: $0
Accepted by SEC: 04 Jan 2023, 15:22
Role: Director
Next action: Open filing details

4

ImmunoGen, Inc.

Report period: 30 Sep 2022
Transactions: 1
Transaction value: $0
Accepted by SEC: 04 Oct 2022, 16:14
Role: Director
Next action: Open filing details

4

ImmunoGen, Inc.

Report period: 30 Jun 2022
Transactions: 1
Transaction value: $0
Accepted by SEC: 05 Jul 2022, 16:36
Role: Director
Next action: Open filing details

4

IDERA PHARMACEUTICALS, INC.

Report period: 23 Jun 2022
Transactions: 1
Transaction value: $0
Accepted by SEC: 27 Jun 2022, 16:31
Role: Director
Next action: Open filing details

4 BPMC

Blueprint Medicines Corp

Report period: 21 Jun 2022
Transactions: 2
Transaction value: $0
Accepted by SEC: 30 Jun 2022, 21:55
Role: Director
Next action: Open filing details

4

ImmunoGen, Inc.

Report period: 15 Jun 2022
Transactions: 2
Transaction value: +$148,280
Accepted by SEC: 17 Jun 2022, 16:22
Role: Director
Next action: Open filing details

4 GLYC

GLYCOMIMETICS INC

Report period: 18 May 2022
Transactions: 1
Transaction value: $0
Accepted by SEC: 20 May 2022, 16:08
Role: Director
Next action: Open filing details

4/A

ImmunoGen, Inc.

Report period: 31 Mar 2022
Transactions: 1
Transaction value: $0
Accepted by SEC: 20 Apr 2022, 17:38
Role: Director
Next action: Open filing details

4 BPMC

Blueprint Medicines Corp

Report period: 03 Mar 2022
Transactions: 1
Transaction value: +$299,900
Accepted by SEC: 07 Mar 2022, 15:05
Role: Director
Next action: Open filing details

4

ImmunoGen, Inc.

Report period: 31 Dec 2021
Transactions: 1
Transaction value: $0
Accepted by SEC: 04 Jan 2022, 15:02
Role: Director
Next action: Open filing details

4

ImmunoGen, Inc.

Report period: 30 Sep 2021
Transactions: 1
Transaction value: $0
Accepted by SEC: 01 Oct 2021, 16:14
Role: Director
Next action: Open filing details

4

ImmunoGen, Inc.

Report period: 30 Jun 2021
Transactions: 1
Transaction value: $0
Accepted by SEC: 02 Jul 2021, 16:22
Role: Director
Next action: Open filing details

4

ImmunoGen, Inc.

Report period: 16 Jun 2021
Transactions: 2
Transaction value: +$297,880
Accepted by SEC: 17 Jun 2021, 16:23
Role: Director
Next action: Open filing details

4

IDERA PHARMACEUTICALS, INC.

Report period: 08 Jun 2021
Transactions: 1
Transaction value: $0
Accepted by SEC: 10 Jun 2021, 17:06
Role: Director
Next action: Open filing details

4 BPMC

Blueprint Medicines Corp

Report period: 02 Jun 2021
Transactions: 2
Transaction value: $0
Accepted by SEC: 04 Jun 2021, 16:21
Role: Director
Next action: Open filing details

4 GLYC

GLYCOMIMETICS INC

Report period: 18 May 2021
Transactions: 2
Transaction value: $0
Accepted by SEC: 27 May 2021, 20:51
Role: Director
Next action: Open filing details

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. to update or revoke optional consent for future visits. For more information, see our Privacy Policy .